Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Underrepresentation of Older Adults in Clinical Trials of Chimeric Antigen Receptor (CAR) T-Cell Therapy for Hematologic Malignancies: An FDA Analysis

Pamela Seam, Upendra Mahat, Najat Bouchkouj, Poornima Sharma, Helka Peredo-Pinto, Mona Elmacken, Megha Kaushal, Yuxia Jia, Shu Wang, Zhiheng Xu, Yvette Kasamon, Bindu Kanaparu, Nicholas Richardson, Nicole Gormley

Blood (2023) 142 (Supplement 1): 6919.

https://doi.org/10.1182/blood-2023-186544

Published: 2023

Journal Articles

Underrepresentation of Racial and Ethnic Minorities in Registrational Chimeric Antigen Receptor (CAR) T-Cell Therapy Trials in Hematologic Malignancies: An FDA Analysis

Upendra Mahat, Pamela Seam, Najat Bouchkouj, Poornima Sharma, Helka Peredo-Pinto, Mona Elmacken, Megha Kaushal, Shu Wang, Zhiheng Xu, Yuxia Jia, Nicholas Richardson, Bindu Kanapuru, Yvette Kasamon, Nicole Gormley

Blood (2023) 142 (Supplement 1): 4874.

https://doi.org/10.1182/blood-2023-182279

Published: 2023

Journal Articles

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease

Leo Luznik, Javier Bolaños-Meade, Marianna Zahurak, Allen R. Chen, B. Douglas Smith, Robert Brodsky, Carol Ann Huff, Ivan Borrello, William Matsui, Jonathan D. Powell, Yvette Kasamon, Steven N. Goodman, Allan Hess, Hyam I. Levitsky, Richard F. Ambinder, Richard J. Jones, Ephraim J. Fuchs

Blood (2010) 115 (16): 3224–3230.

https://doi.org/10.1182/blood-2009-11-251595

Published: 2010

Journal Articles

Clonotypic B Cells Circulate in Hodgkin’s Lymphoma (HL).

Richard J. Jones, MD, Lan Lin, M.D., Christopher Gocke, M.D., Kortney Hensley, Mark Siedner, James P. Barber, Yvette Kasamon, M.D., Richard F. Ambinder, M.D., Ph.D, William Matsui, M.D.

Blood (2006) 108 (11): 470.

https://doi.org/10.1182/blood.V108.11.470.470

Published: 2006

Journal Articles

Characterization of Vaccine Site and Cellular Infiltrate in Subjects with Chronic Myeloid Leukemia (CML) Receiving K562/GM-CSF Vaccination in Combination with Imatinib Mesylate with or without Topical Imiquimod.

Christina Y. Chia, MD, B. Douglas Smith, MD, Yvette Kasamon, MD, Carole B. Miller, MD, Mary E. Brummet, MS, Lora Bankova, MD, Jeanne Kowalski, PhD, Barbara Biedrzycki, MSN, Kristen Hege, Lisa A. Beck, MD, Hyam Levitsky, MD

Blood (2005) 106 (11): 2399.

https://doi.org/10.1182/blood.V106.11.2399.2399

Published: 2005

NARROW

Underrepresentation of Older Adults in Clinical Trials of Chimeric Antigen Receptor (CAR) T-Cell Therapy for Hematologic Malignancies: An FDA Analysis

Underrepresentation of Racial and Ethnic Minorities in Registrational Chimeric Antigen Receptor (CAR) T-Cell Therapy Trials in Hematologic Malignancies: An FDA Analysis

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease

Clonotypic B Cells Circulate in Hodgkin’s Lymphoma (HL).

Characterization of Vaccine Site and Cellular Infiltrate in Subjects with Chronic Myeloid Leukemia (CML) Receiving K562/GM-CSF Vaccination in Combination with Imatinib Mesylate with or without Topical Imiquimod.

Email alerts

ASH Publications

American Society of Hematology

Underrepresentation of Older Adults in Clinical Trials of Chimeric Antigen Receptor (CAR) T-Cell Therapy for Hematologic Malignancies: An FDA Analysis

Underrepresentation of Racial and Ethnic Minorities in Registrational Chimeric Antigen Receptor (CAR) T-Cell Therapy Trials in Hematologic Malignancies: An FDA Analysis

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease

Clonotypic B Cells Circulate in Hodgkin’s Lymphoma (HL).

Characterization of Vaccine Site and Cellular Infiltrate in Subjects with Chronic Myeloid Leukemia (CML) Receiving K562/GM-CSF Vaccination in Combination with Imatinib Mesylate with or without Topical Imiquimod.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only